Strengths of this risk prediction model for Barrett's includes the relatively large number of cases and an external validation dataset. A limitation is that only those with symtomatic GERD (reflux) were included, so
This review paper summarizes some of the current issues in surveillance and treatment after endoscopic eradication therapy (e.g., RFA) for Barrett's dysplasia. Am J Gastroenterol. 2020 Jan 3. doi: 10.14309/ajg.
Investigators in the CISNET Esophagus consortium employed comparative modeling to develop recommendations on clinical management (surveillance frequency and endoscopic eradication therapy) of persons with low grade or non-dysplastic Barrett's esophagus. Clin Gastroenterol Hepatol.
While not breaking any new ground, this large meta-analysis observed that older age, male sex, smoking, longer BE segment, and LGD were predictive of progression of BE to dysplasia or cancer. Clinical Gastro
This study from Kaiser Permanente Northern California oberved that early onset of reflux symptoms approximately doubles risk of Barrett's esophagus, and that both severity and frequency of reflux symptoms are important in predicting